Currently, TIL therapy is approved by the US Food and Drug Administration for patient with advanced (metastatic) melanoma. Not all patients with metastatic melanoma automatically qualify for TIL therapy. Determining if a patient is a candidate for TIL therapy is based on many factors, including cancer stage, overall health, prior treatments.

Candidates must have previously undergone and failed BRAF inhibitors or PD-1 therapy, a standard checkpoint inhibitor treatment. In addition, physicians assess organ function and performance status to ensure the patient can tolerate the therapy. Social support is another critical factor, as patients needreliable transportation and assistance throughout their treatment journey.

There are clinical trials open to study the use of TIL therapy in other solid tumor cancers.